Übersetzung für "lifetime use " (Englisch → Französisch) :

carrier lifetime | excess minority-carrier lifetime | lifetime | minority-carrier lifetime

pellet lifetime | pellet life-time | pellet life time | lifetime | life time | life-time | pellet ablation time | ablation time | life-time/ lifetime | life time/lifetime

bulk electron lifetime | bulk hole lifetime | bulk-carrier lifetime

The Lifetime Capital Gains Exemption: an evaluation [ The Lifetime Capital Gains Exemption: an evaluation: summary of the findings of a symposium on the Lifetime Capital Gains Exemption sponsored by the Institute for Policy Analysis of the University of Toronto and the Department of Finance. ]

lifetime limit [ lifetime maximum | maximum lifetime benefit ]

chlorofluorocarbon lifetime [ CFC lifetime | fluorocarbon lifetime | chlorofluorocarbon residence time | CFC residence time | fluorocarbon residence time ]

cycle lifetime | cycle life | cycling lifetime | cycling life

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include sel ...[+++]f-report data, analysis of blood and other body fluids, characteristic physical and psychological symptoms, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

Youth-focused programming that discourages involvement in drugs in the first place is essential to preventing the earlier onset of drug use and the harms of prolonged use across one's lifetime.

(Return tabled) Question No. 57 Mr. Scott Simms: With regard to copyrighted material held by the government: (a) what copyrighted material does the government own, broken down by (i) department, (ii) creation date, (iii) publication date, (iv) author, (v) fee charged for use, (vi) total fees collected to date in the lifetime of the material, (vii) format or media type, (viii) cost of production, (ix) future plans, (x) for any material not available to the public, what are the reasons for the secrecy and the name and title of the person responsible for the decision to keep the material from the public; and (b) what enforcement action has ...[+++] the government taken to protect its copyright on any material since January, 2006, broken down by (i) department, (ii) creation date, (iii) publication date, (iv) author, (v) fee charged for use, (vi) total fees collected to date in the lifetime of the material, (vii) alleged infraction, (viii) damages sought, (ix) case status, (x) case outcome or settlement?

(Return tabled) Question No. 286 Mr. Alex Atamanenko: With regard to the horse slaughter industry in Canada: (a) does the government know whether third party monitoring of video footage is occurring at Viandes Richelieu and Bouvry Exports and, if so, (i) what is the monitoring criteria, (ii) who is monitoring the footage, (iii) what actions, if any, have been taken as a result of observations, (iv) is footage monitoring to be a daily practice at this and other Canadian horse slaughter plants, (v) how many hours have been monitored, (vi) is footage archived and for how long, (vii) does the recording continuously loop over previous footage; (b) which tissue types and/or bodily fluids are targeted by the government when testing for phenylbuta ...[+++]zone and other drugs in horsemeat, (i) what percentage of drug testing is performed on equine organs (particularly kidney and liver) as opposed to other tissues, such as muscle, (ii) what is the exact methodology and what are the specific testing mechanisms used to detect phenylbutazone and other drugs in horsemeat; (c) what surveys or studies has the government undertaken or relied on to determine the number of overall horse owners and keepers that have administered to horses under their care, even once in the horse's lifetime, substances that are banned for human consumption, in (i) Canada, (ii) the United States (US); (d) what surveys or studies encompassing the overall horse population has the government undertaken or relied on to determine the percentage of veterinarians who routinely administer to horse patients under their care, at any time in the horse's lifetime, substances that are banned for use in food animals, in (i) Canada, (ii) the US; (e) what was the ratio between the number of horses and the number of prescriptions of substances banned for use in food animals at any time in their lifetime, issued by veterinarians to the overall horse population in (i) Canada, (ii) the US; (f) what were the results of European ...

The life cycle cost analysis method uses a real discount rate on the basis of data provided from the European Central Bank and a realistic lifetime for the product; it is based on the sum of the variations in purchase price (resulting from the variations in industrial costs) and in operating expenses, which result from the different levels of technical improvement options, discounted over the lifetime of the representative product models considered.